AdalimumabQualityChecker

Adalimumab

API assay biologics biosimilars endotoxins fixed-dose combinations generics impurities
Open selection
Adalimumab Quality Checker — Biologic Drug (Monoclonal Antibody) (Ph. Eur., USP, ICH Q6B)

ℹ️  The utility checks aggregates, charge variants, HCP, DNA, subvisible particles, sterility.
ℹ️  Does not use machine learning — rule-based logic only.
⚠️  CRITICAL! Aggregates ≤1% (immunogenicity), HCP ≤100 ppm, DNA ≤10 ng/mL, sterility!

Usage:
  AdalimumabQualityChecker.exe                            → demo mode
  AdalimumabQualityChecker.exe input.csv output.json      → evaluate data

Input format:
BatchNumber,Protein_Concentration_mgPerMl,pH_Value,Osmolality_mOsm_kg,Aggregate_Percent_SEC,Fragment_Percent_SEC,Acidic_Variants_Percent_IEC,Basic_Variants_Percent_IEC,Main_Peak_Percent_IEC,Glycosylation_NonGlycosylated_Percent,Host_Cell_Protein_ppm,Residual_DNA_ngPerMl,Protein_A_Leaching_ngPerMl,Subvisible_Particles_2_10_um,Subvisible_Particles_10_25_um,Subvisible_Particles_gt_25_um,SterilityTest,Endotoxin_EU_ml,Potency_Relative_Percent

Example:
ADA-BIO-2026-001,40.5,5.2,280,0.4,0.3,18.0,8.0,74.0,1.5,45,2.5,1.2,3500,400,15,0,0.05,98.0

— WHY IS THIS NEEDED?
Adalimumab — recombinant human monoclonal antibody (IgG1). QC for biologics is more complex than small molecules:
• Aggregates (HMW): Main risk of immunogenicity (Anti-Drug Antibodies - ADA). Limit is strict (≤1%).
• Charge Variants (IEC): Acidic/Basic peaks show deamidation, oxidation, glycosylation changes.
• Process Impurities: Host Cell Protein (HCP) and DNA must be removed to trace levels (ppm, ng/mL).
• Subvisible Particles: Micro-inclusions visible only under microscope or particle counter. Critical for vein/capillary safety.
• Potency: Biological activity (TNF-α neutralization) must be within 70-130%.
⚠️ CRITICAL:
• Aggregates ≤ 1.0% (SEC-HPLC) — exceedance leads to batch recall due to anaphylaxis risk.
• HCP ≤ 100 ppm — residual CHO/NS0 cell protein can be allergen.
• DNA ≤ 10 ng/mL — risk of oncogenicity/infection.
• Sterility and Endotoxins — absolutely mandatory for injections.
• Particles >25 µm ≤ 60 counts/mL — USP <788> standard.
⚠️ Note: Utility combines data from chromatography (SEC, IEC), mass spectrometry (glycosylation), ELISA (HCP, Protein A), and particle counting. For biologics, "specification" is a range, not exact number, as it's a living product. Any deviation in aggregates or sterility is critical.

input.csv

BatchNumber,Protein_Concentration_mgPerMl,pH_Value,Osmolality_mOsm_kg,Aggregate_Percent_SEC,Fragment_Percent_SEC,Acidic_Variants_Percent_IEC,Basic_Variants_Percent_IEC,Main_Peak_Percent_IEC,Glycosylation_NonGlycosylated_Percent,Host_Cell_Protein_ppm,Residual_DNA_ngPerMl,Protein_A_Leaching_ngPerMl,Subvisible_Particles_2_10_um,Subvisible_Particles_10_25_um,Subvisible_Particles_gt_25_um,SterilityTest,Endotoxin_EU_ml,Potency_Relative_Percent
ADA-BIO-2026-001,40.5,5.2,280,0.4,0.3,18.0,8.0,74.0,1.5,45,2.5,1.2,3500,400,15,0,0.05,98.0

URS & FS — user requirements and functional specification

This document defines user requirements and functional specification for the quality-control utility. It supports deployment discussion, IQ/OQ preparation and QC workflow integration.

Utility: AdalimumabQualityCheckerAPI / object: AdalimumabCategory: Global API

1. Scope

The Adalimumab Quality Checker utility is used for Adalimumab. The actual input.csv is the source of truth for the input structure; control criteria are defined by the executable and the domain description.

The utility does not use machine learning; decisions are produced by deterministic rules.

Categories: Global API

Tags: API, assay, biologics, biosimilars, endotoxins, fixed-dose combinations, generics, impurities, injectables, market map, sterility

2. Execution modes

AdalimumabQualityChecker.exe                            → demo mode
AdalimumabQualityChecker.exe input.csv output.json      → evaluate data

3. Key controlled areas

  • assay / content
  • microbiology and pathogens
  • pH and physicochemical parameters

4. Domain limits and critical parameters

  • ⚠️ CRITICAL! Aggregates ≤1% (immunogenicity), HCP ≤100 ppm, DNA ≤10 ng/mL, sterility!
  • Aggregates (HMW): Main risk of immunogenicity (Anti-Drug Antibodies - ADA). Limit is strict (≤1%).
  • ⚠️ CRITICAL:
  • Aggregates ≤ 1.0% (SEC-HPLC) — exceedance leads to batch recall due to anaphylaxis risk.
  • HCP ≤ 100 ppm — residual CHO/NS0 cell protein can be allergen.
  • DNA ≤ 10 ng/mL — risk of oncogenicity/infection.
  • Sterility and Endotoxins — absolutely mandatory for injections.
  • Particles >25 µm ≤ 60 counts/mL — USP <788> standard.
  • ⚠️ Note: Utility combines data from chromatography (SEC, IEC), mass spectrometry (glycosylation), ELISA (HCP, Protein A), and particle counting. For biologics, "specification" is a range, not exact number, as it's a living product. Any deviation in aggregates or sterility is critical.
Limits stated in the description must be verified against the current approved specification, pharmacopoeial monograph and registration dossier before production use.

5. URS — user requirements

IDRequirementCriticalityAcceptance criterion
URS-001The system shall accept an input.csv file for Adalimumab with the exact columns listed in the “Input data contract” section.HighA file with the correct header is processed without manual editing; missing mandatory columns produce FAIL/import error.
URS-002The system shall support execution without arguments in demo mode and execution with input.csv output.json for user data.MediumBoth execution scenarios produce a predictable result or clear diagnostic error.
URS-003The system shall perform rule-based controls for: assay / content, microbiology and pathogens, pH and physicochemical parameters.HighEach controlled parameter receives a status and message; the result does not depend on hidden Excel formulas or ML.
URS-004The system shall preserve traceability between batch/lot, source values, applied rules and final verdict.HighOutput includes batch identifier, source values, parameter statuses and critical findings.
URS-005The system shall generate machine-readable output.json for LIMS/ELN/MES, batch record and QA/QC review.HighJSON contains overall status, check array, warnings, failures and source-file reference.
URS-006The system shall support use in the client validation package: URS/FS, IQ/OQ preparation, installation and operational scenario checks.HighThe document, test scenarios and reproducible CSV/JSON flow are suitable for audit and internal approval.
URS-007The system shall clearly separate technical data errors from specification nonconformities.MediumSchema/type errors are not mixed with pharmacopoeial deviations and are reported separately.

6. input.csv data contract

The source of truth for the input schema is the actual input.csv header. Column names are technical identifiers and are not translated.

#ColumnTypeUnitDescriptionSampleControl rule
1BatchNumberidentifieras specifiedBatch NumberADA-BIO-2026-001mandatory field; used for batch/lot traceability
2Protein_Concentration_mgPerMldecimalmg/mlProtein Concentration mg per Ml40.5numeric value; compared with assay/purity limit from specification or method
3pH_ValuedecimalpHp H Value5.2mandatory numeric value; rule comparison is performed by the utility
4Osmolality_mOsm_kgdecimalmOsm/kgOsmolality m Osm kg280mandatory numeric value; rule comparison is performed by the utility
5Aggregate_Percent_SECdecimal%Aggregate % SEC0.4mandatory numeric value; rule comparison is performed by the utility
6Fragment_Percent_SECdecimal%Fragment % SEC0.3mandatory numeric value; rule comparison is performed by the utility
7Acidic_Variants_Percent_IECdecimal%Acidic Variants % IEC18.0mandatory numeric value; rule comparison is performed by the utility
8Basic_Variants_Percent_IECdecimal%Basic Variants % IEC8.0mandatory numeric value; rule comparison is performed by the utility
9Main_Peak_Percent_IECdecimal%Main Peak % IEC74.0mandatory numeric value; rule comparison is performed by the utility
10Glycosylation_NonGlycosylated_Percentdecimal%Glycosylation Non Glycosylated %1.5mandatory numeric value; rule comparison is performed by the utility
11Host_Cell_Protein_ppmdecimalppmHost Cell Protein ppm45mandatory numeric value; rule comparison is performed by the utility
12Residual_DNA_ngPerMldecimalas specifiedResidual DNA ng per Ml2.5mandatory numeric value; rule comparison is performed by the utility
13Protein_A_Leaching_ngPerMldecimalas specifiedProtein A Leaching ng per Ml1.2mandatory numeric value; rule comparison is performed by the utility
14Subvisible_Particles_2_10_umdecimalµmSubvisible Particles 2 10 um3500mandatory numeric value; rule comparison is performed by the utility
15Subvisible_Particles_10_25_umdecimalµmSubvisible Particles 10 25 um400mandatory numeric value; rule comparison is performed by the utility
16Subvisible_Particles_gt_25_umdecimalµmSubvisible Particles gt 25 um15mandatory numeric value; rule comparison is performed by the utility
17SterilityTestboolean / flag0/1Sterility Test0valid flag required; prohibited organisms and growth are normally expected as 0 / absent
18Endotoxin_EU_mldecimalas specifiedEndotoxin EU ml0.05numeric value; critical safety attribute compared with endotoxin limit
19Potency_Relative_Percentdecimal%Potency Relative %98.0mandatory numeric value; rule comparison is performed by the utility

CSV example

BatchNumber,Protein_Concentration_mgPerMl,pH_Value,Osmolality_mOsm_kg,Aggregate_Percent_SEC,Fragment_Percent_SEC,Acidic_Variants_Percent_IEC,Basic_Variants_Percent_IEC,Main_Peak_Percent_IEC,Glycosylation_NonGlycosylated_Percent,Host_Cell_Protein_ppm,Residual_DNA_ngPerMl,Protein_A_Leaching_ngPerMl,Subvisible_Particles_2_10_um,Subvisible_Particles_10_25_um,Subvisible_Particles_gt_25_um,SterilityTest,Endotoxin_EU_ml,Potency_Relative_Percent
ADA-BIO-2026-001,40.5,5.2,280,0.4,0.3,18.0,8.0,74.0,1.5,45,2.5,1.2,3500,400,15,0,0.05,98.0

7. FS — functional specification

IDFunctionImplementation description
FS-001CLI entry pointThe executable AdalimumabQualityChecker.exe supports demo mode and input.csv output.json processing mode.
FS-002CSV parserThe import module reads CSV, validates header, column presence/order, value count and encoding. Decimal values are expected with a dot separator.
FS-003Field conversionEach column is converted to the expected type: identifier, text, decimal number, date/time or boolean flag.
FS-004Domain rule engineFor Adalimumab, explicit rules are applied: range, minimum, maximum, absence of prohibited flag, data completeness or calculation-based check.
FS-005Criticality handlingCritical violations produce FAIL; non-critical deviations and incomplete data produce WARNING; full conformance produces PASS.
FS-006JSON writeroutput.json stores overall status, per-parameter results, source values, warnings, failures and diagnostic messages.
FS-007Integration contractThe CSV → JSON format is stable for invocation from LIMS/ELN/MES, scheduled task or wrapper service.
FS-008Error handlingSchema error, missing file, non-numeric value or JSON write failure returns diagnosable error without silent PASS.

8. output.json contract

The output file must be suitable for automated processing, audit review and correlation with the source input.csv row.

{
  "utility": "AdalimumabQualityChecker",
  "api": "Adalimumab",
  "batchNumber": "ADA-BIO-2026-001",
  "overallStatus": "PASS|WARNING|FAIL",
  "checkedAtUtc": "2026-05-18T00:00:00Z",
  "checks": [
    {
      "parameter": "BatchNumber",
      "value": "ADA-BIO-2026-001",
      "unit": "as specified",
      "status": "PASS|WARNING|FAIL",
      "message": "Rule-based check result"
    },
    {
      "parameter": "Protein_Concentration_mgPerMl",
      "value": "40.5",
      "unit": "mg/ml",
      "status": "PASS|WARNING|FAIL",
      "message": "Rule-based check result"
    },
    {
      "parameter": "pH_Value",
      "value": "5.2",
      "unit": "pH",
      "status": "PASS|WARNING|FAIL",
      "message": "Rule-based check result"
    },
    {
      "parameter": "Osmolality_mOsm_kg",
      "value": "280",
      "unit": "mOsm/kg",
      "status": "PASS|WARNING|FAIL",
      "message": "Rule-based check result"
    },
    {
      "parameter": "Aggregate_Percent_SEC",
      "value": "0.4",
      "unit": "%",
      "status": "PASS|WARNING|FAIL",
      "message": "Rule-based check result"
    },
    {
      "parameter": "Fragment_Percent_SEC",
      "value": "0.3",
      "unit": "%",
      "status": "PASS|WARNING|FAIL",
      "message": "Rule-based check result"
    },
    {
      "parameter": "Acidic_Variants_Percent_IEC",
      "value": "18.0",
      "unit": "%",
      "status": "PASS|WARNING|FAIL",
      "message": "Rule-based check result"
    },
    {
      "parameter": "Basic_Variants_Percent_IEC",
      "value": "8.0",
      "unit": "%",
      "status": "PASS|WARNING|FAIL",
      "message": "Rule-based check result"
    }
  ],
  "criticalFindings": [],
  "sourceFile": "input.csv"
}

9. OQ/PQ test scenarios

IDScenarioExpected result
TC-001Valid CSV with expected header and sample rowAll rows are processed; output contains PASS/WARNING/FAIL and parameter-level detail.
TC-002A mandatory input.csv column is missingImport is rejected or the row receives FAIL with schema reference.
TC-003A numeric field contains text or a blank valueType conversion error is recorded; the result is not hidden as PASS.
TC-004A parameter is outside specification or critical limitCritical parameters produce FAIL; non-critical deviations produce WARNING according to the rule.
TC-005Positive pathogen/microbiological flag or microbiological limit excursionCritical FAIL is produced with the offending parameter.

10. QA/QC, CSV and change control

  • Before production use, the client records executable version, checksum, specification/monograph version, test CSV, expected JSON and IQ/OQ results.
  • Column names must not be changed without updating the validator and test scenarios.
  • The source CSV, output.json and utility version should be stored together as an evidence package.
  • Any change in control rules must go through change control and repeated OQ scenario verification.

Included in packages

Australia: national essential medicines QC package

QC utility package aligned with the country essential/reimbursed medicines list analogue and cross-checked against WHO EML. Only utilities already present in the portal are included; the package is a validation/discussion starting map, not an official registry copy.

Open

Biopharmaceuticals Core QC Suite

Focused QC utility package for biologic products: HCP, mAbs, biosimilars, proteins/peptides, sterility, endotoxins and key release checks.

Open

Biopharmaceuticals Extended QC Suite

Extended QC utility coverage for mAbs, biosimilars, proteins, insulins, vaccines, mRNA/LNP, HCP, sterile release, microbiology, water, cleanroom and stability workflows.

Open

Canada: national essential medicines QC package

QC utility package aligned with the country essential/reimbursed medicines list analogue and cross-checked against WHO EML. Only utilities already present in the portal are included; the package is a validation/discussion starting map, not an official registry copy.

Open

France: national essential medicines QC package

QC utility package aligned with the country essential/reimbursed medicines list analogue and cross-checked against WHO EML. Only utilities already present in the portal are included; the package is a validation/discussion starting map, not an official registry copy.

Open

Germany: national essential medicines QC package

QC utility package aligned with the country essential/reimbursed medicines list analogue and cross-checked against WHO EML. Only utilities already present in the portal are included; the package is a validation/discussion starting map, not an official registry copy.

Open

Global API & Biosimilars QC Suite

Package for high-demand global APIs, generics and biosimilars, including fixed-dose combinations and biological products.

Open

Immunology QC Suite

QC utility package for immunology: monoclonal antibodies, biosimilars, immunomodulators, immunosuppressants, ELISA/SPR, HCP, protein characterization, sterility and pyrogen/release checks.

Open

Italy: national essential medicines QC package

QC utility package aligned with the country essential/reimbursed medicines list analogue and cross-checked against WHO EML. Only utilities already present in the portal are included; the package is a validation/discussion starting map, not an official registry copy.

Open

Japan: national essential medicines QC package

QC utility package aligned with the country essential/reimbursed medicines list analogue and cross-checked against WHO EML. Only utilities already present in the portal are included; the package is a validation/discussion starting map, not an official registry copy.

Open

Radiology QC Suite

QC package for radiology and diagnostic imaging: radiopharmaceuticals, PET/SPECT, contrast media, iodinated and gadolinium products, plus particle, sterility and endotoxin checks.

Open

Rheumatology QC Suite

QC package for rheumatology: NSAIDs, glucocorticoids, methotrexate, biologics and supporting impurity/potency checks.

Open

Russia: national essential medicines QC package

QC utility package aligned with the country essential/reimbursed medicines list analogue and cross-checked against WHO EML. Only utilities already present in the portal are included; the package is a validation/discussion starting map, not an official registry copy.

Open

Saudi Arabia: national essential medicines QC package

QC utility package aligned with the country essential/reimbursed medicines list analogue and cross-checked against WHO EML. Only utilities already present in the portal are included; the package is a validation/discussion starting map, not an official registry copy.

Open

South Korea: national essential medicines QC package

QC utility package aligned with the country essential/reimbursed medicines list analogue and cross-checked against WHO EML. Only utilities already present in the portal are included; the package is a validation/discussion starting map, not an official registry copy.

Open

United Kingdom: national essential medicines QC package

QC utility package aligned with the country essential/reimbursed medicines list analogue and cross-checked against WHO EML. Only utilities already present in the portal are included; the package is a validation/discussion starting map, not an official registry copy.

Open

United States: national essential medicines QC package

QC utility package aligned with the country essential/reimbursed medicines list analogue and cross-checked against WHO EML. Only utilities already present in the portal are included; the package is a validation/discussion starting map, not an official registry copy.

Open